Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alzheimer

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   38159   clinical trials with a EudraCT protocol, of which   6268   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    Select Age Range:
    Select Trial Status:
    Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    72 result(s) found for: Alzheimer. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2014-001315-40 Sponsor Protocol Number: RF-2010-2319722 Start Date*: 2014-12-03
    Sponsor Name:IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
    Full Title: Amyloid Imaging in the “Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)”
    Medical condition: Autosomal Dominant Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003405-27 Sponsor Protocol Number: CENA 713D FR08 Start Date*: 2007-09-10
    Sponsor Name:NOVARTIS PHARMA SAS
    Full Title: Etude ouverte, multicentrique, de 24 semaines, évaluant l'efficience clinique de la forme Exelon patch 10 cm2 chez des patients avec une maladie d'Alzheimer (MMSE 10-26)
    Medical condition: Maladie d'Alzheimer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-002783-88 Sponsor Protocol Number: 331-201-00182 Start Date*: 2018-12-27
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheim...
    Medical condition: Agitation Associated With Dementia of the Alzheimer's Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Ongoing) ES (Ongoing) HU (Ongoing) SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002147-34 Sponsor Protocol Number: AZT-001 Start Date*: 2016-01-21
    Sponsor Name:AZTherapies, Inc.
    Full Title: A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.
    Medical condition: Early stage of Alzheimer's Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) CZ (Ongoing) BG (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004474-15 Sponsor Protocol Number: PETFLUTEMETAMOL-FDG/BBRC2015 Start Date*: 2016-03-14
    Sponsor Name:BarcelonaBeta Brain Research Center
    Full Title: Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and of glucose metabolism with 18F-FDG PET in individuals enrolled in the ALFA project
    Medical condition: Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004865 10036654 Prevention LLT
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-003362-17 Sponsor Protocol Number: MPC-7869-05-009.02 Start Date*: 2008-01-04
    Sponsor Name:Myriad Pharmaceuticals, Inc
    Full Title: Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer’s Type
    Medical condition: Treatment of Alzheimer’s disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) BE (Completed) DE (Prematurely Ended) NL (Ongoing) SE (Prematurely Ended) DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006490-24 Sponsor Protocol Number: CL-758019 Start Date*: 2007-04-19
    Sponsor Name:Neurochem Inc
    Full Title: An Open-Label Extension of the Phase III Study CL-758010 with Alzhemed™ in Patients with Alzheimer’s Disease.
    Medical condition: Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disorder, characterized by gradual cognitive decline, abnormal behaviour, and personality changes.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Ongoing) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-003940-19 Sponsor Protocol Number: 331-14-213 Start Date*: 2018-08-06
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, 12-Week, Multicenter, Randomized, Double-blind, Placebo controlled, 2 Arm, Fixed-dose Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) in the Treatme...
    Medical condition: Agitation Associated With Dementia of the Alzheimer’s Type
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Ongoing) ES (Ongoing) HU (Ongoing) SK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002005-19 Sponsor Protocol Number: TTP488-301 Start Date*: 2016-08-19
    Sponsor Name:vTv THERAPEUTICS LLC
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE ...
    Medical condition: MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTINE
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10012268 Dementia (excl Alzheimer's type) HLT
    20.0 10029205 - Nervous system disorders 10012296 Dementia of the Alzheimer's type, with depressed mood PT
    20.0 10029205 - Nervous system disorders 10012295 Dementia of the Alzheimer's type, with delusions PT
    20.0 10029205 - Nervous system disorders 10012294 Dementia of the Alzheimer's type, with delirium PT
    20.0 10029205 - Nervous system disorders 10012293 Dementia of the Alzheimer's type, uncomplicated PT
    20.0 10029205 - Nervous system disorders 10012292 Dementia of the Alzheimer's type NOS LLT
    20.0 10029205 - Nervous system disorders 10066571 Progression of Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001119-54 Sponsor Protocol Number: H8A-MC-LZAX Start Date*: 2013-09-27
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo
    Medical condition: Mild Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Ongoing) SE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006352-22 Sponsor Protocol Number: DIM14EXT Start Date*: 2009-07-14
    Sponsor Name:Medivation, Inc.
    Full Title: CONNECTION PLUS: An Open-Label Extension of the CONNECTION Protocol (DIM14) Evaluating Oral Dimebon in Patients with Alzheimer’s Disease
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing) NL (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003440-36 Sponsor Protocol Number: I8D-MC-AZFD Start Date*: 2017-06-12
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Delayed-Start Study of LY3314814 (AZD3293) in Early Alzheimer’s Disease Dementia (Extension of Study AZES, The AMARANTH Study)
    Medical condition: Early Alzheimer's Disease (mild cognitive impairment due to AD (ie, prodromal AD) and mild dementia of the Alzheimer's type)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) DE (Prematurely Ended) PL (Completed) ES (Ongoing) BE (Ongoing) GB (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2004-004918-17 Sponsor Protocol Number: A2501046 Start Date*: 2005-04-01
    Sponsor Name:Pfizer Inc.
    Full Title: A 12-week, open label, multicentre study assessing the efficcay and of Donepezil in patients discontinuing treatment with Memantine monotherapy
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    7 10012271 VTc
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) CZ (Completed) DE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004739-58 Sponsor Protocol Number: BAN2401-G000-301 Start Date*: 2019-06-12
    Sponsor Name:Eisai Limited
    Full Title: A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease
    Medical condition: Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) DE (Ongoing) ES (Ongoing) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012569-79 Sponsor Protocol Number: BAY94-9172/14595 Start Date*: 2012-01-09
    Sponsor Name:Bayer AG
    Full Title: An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when com...
    Medical condition: Detection/Exclusion of cerebral ß-amyloid. To determine the sensitivity and specificity of the visual assessment of regional tracer uptake in the BAY 94-9172 PET images compared to histological ...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2012-002866-11 Sponsor Protocol Number: TRx-237-015 Start Date*: 2013-01-23
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 15-Month Trial of Leuco-methylthioninium bis(hydromethanesulfonate) in Subjects with Mild to Moderate Alzheimer's Disease
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Ongoing) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-003558-17 Sponsor Protocol Number: TRx-237-039 Start Date*: 2018-02-25
    Sponsor Name:TauRx Therapeutics Ltd
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer's Disease Followed by a 12...
    Medical condition: Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Ongoing) BE (Ongoing) PL (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000001-23 Sponsor Protocol Number: 14861B Start Date*: 2014-02-27
    Sponsor Name:H. Lundbeck A/S
    Full Title: An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease
    Medical condition: Alzheimer´s disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) EE (Completed) IT (Ongoing) BE (Completed) LT (Completed) ES (Completed) DK (Completed) BG (Completed) PT (Completed) GB (Completed) HU (Completed) FI (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021155-11 Sponsor Protocol Number: H8A-MC-LZAO Start Date*: 2010-11-29
    Sponsor Name:Eli Lilly and Company
    Full Title: Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid β Antibody in Patients with Alzheimer’s Disease
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Completed) IT (Ongoing) SE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005118-37 Sponsor Protocol Number: H6L-MC-LFAN (e) Start Date*: 2008-12-15
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of γ-Secretase Inhibition on the Progression of Alzheimer’s Disease: LY450139 versus Placebo
    Medical condition: Alzheimers Disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Ongoing) FI (Completed) ES (Prematurely Ended) DE (Prematurely Ended) BE (Ongoing) GR (Prematurely Ended) SE (Prematurely Ended) DK (Completed) IT (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA